These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33133727)

  • 1. Recent advances in construction of small molecule-based fluorophore-drug conjugates.
    Lang W; Yuan C; Zhu L; Du S; Qian L; Ge J; Yao SQ
    J Pharm Anal; 2020 Oct; 10(5):434-443. PubMed ID: 33133727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disulfide-based multifunctional conjugates for targeted theranostic drug delivery.
    Lee MH; Sessler JL; Kim JS
    Acc Chem Res; 2015 Nov; 48(11):2935-46. PubMed ID: 26513450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy.
    Song X; Han X; Yu F; Zhang X; Chen L; Lv C
    Theranostics; 2018; 8(8):2217-2228. PubMed ID: 29721074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimuli-Responsive Prodrug Chemistries for Cancer Therapy.
    Bargakshatriya R; Pramanik SK
    Chembiochem; 2023 Sep; 24(18):e202300155. PubMed ID: 37341379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A self-immolative prodrug nanosystem capable of releasing a drug and a NIR reporter for in vivo imaging and therapy.
    Wang Z; Wu H; Liu P; Zeng F; Wu S
    Biomaterials; 2017 Sep; 139():139-150. PubMed ID: 28614754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disulfide based prodrugs for cancer therapy.
    Wang Q; Guan J; Wan J; Li Z
    RSC Adv; 2020 Jun; 10(41):24397-24409. PubMed ID: 35516223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.
    Schuster S; Juhász É; Halmos G; Neundorf I; Gennari C; Mező G
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A theranostic prodrug based on FRET for real-time drug release monitoring in response to biothiols.
    Hu Y; Zeng F
    Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():77-85. PubMed ID: 28024642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research advances in peptide‒drug conjugates.
    Gong L; Zhao H; Liu Y; Wu H; Liu C; Chang S; Chen L; Jin M; Wang Q; Gao Z; Huang W
    Acta Pharm Sin B; 2023 Sep; 13(9):3659-3677. PubMed ID: 37719380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modular approach for theranostic polymer conjugates with activatable fluorescence: Impact of linker design on the stimuli-induced release of doxorubicin.
    Nagel G; Tschiche HR; Wedepohl S; Calderón M
    J Control Release; 2018 Sep; 285():200-211. PubMed ID: 30005907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel.
    Wang L; Chen H; Wang F; Zhang X
    Expert Opin Drug Deliv; 2022 Feb; 19(2):147-161. PubMed ID: 35130795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reductively cleavable polymer-drug conjugates based on dendritic polyglycerol sulfate and monomethyl auristatin E as anticancer drugs.
    Rades N; Achazi K; Qiu M; Deng C; Haag R; Zhong Z; Licha K
    J Control Release; 2019 Apr; 300():13-21. PubMed ID: 30794827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment.
    Bocci M; Zana A; Principi L; Lucaroni L; Prati L; Gilardoni E; Neri D; Cazzamalli S; Galbiati A
    J Control Release; 2024 Mar; 367():779-790. PubMed ID: 38346501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smart fluorescent polysaccharides: Recent developments and applications.
    Novo DC; Edgar KJ
    Carbohydr Polym; 2024 Jan; 324():121471. PubMed ID: 37985079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody Conjugates-Recent Advances and Future Innovations.
    Leung D; Wurst JM; Liu T; Martinez RM; Datta-Mannan A; Feng Y
    Antibodies (Basel); 2020 Jan; 9(1):. PubMed ID: 31936270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer.
    Knutson S; Raja E; Bomgarden R; Nlend M; Chen A; Kalyanasundaram R; Desai S
    PLoS One; 2016; 11(6):e0157762. PubMed ID: 27336622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the enzymatic release of MMAE from
    Zambra M; Ranđelović I; Talarico F; Borbély A; Svajda L; Tóvári J; Mező G; Bodero L; Colombo S; Arrigoni F; Fasola E; Gazzola S; Piarulli U
    Front Pharmacol; 2023; 14():1215694. PubMed ID: 37492088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors.
    Sadrerafi K; Mason EO; Lee MW
    Drug Des Devel Ther; 2018; 12():987-995. PubMed ID: 29731606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aptamer-Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells.
    Qi J; Zeng Z; Chen Z; Nipper C; Liu X; Wan Q; Chen J; Tung CH; Zu Y
    Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631384
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.